Top Markets
#1 Siren Siren +34.26%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.83%
#3 Ribbita by Virtuals Ribbita by Virtuals +20.32%
#4 Velvet Velvet +17.54%
#5 Bitway Bitway +17.05%
#6 Wiki Cat Wiki Cat +16.96%
#7 PulseChain PulseChain +16.92%
#8 Cysic Cysic +16.58%
#9 KUB Coin KUB Coin +15.63%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.21%
Coin of the day
Siren Siren
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Clovis Oncology, Inc. Clovis Oncology, Inc.

Clovis Oncology, Inc.

C6O
Classement en actions #30759
Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery,... Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U.S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase. This treatment is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, Rubraca is offered for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Also under development is FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent that specifically acts upon fibroblast activation protein. Rubraca is distributed through a select network of specialty distributors and pharmacies, which then supply the medication to patients and healthcare providers. Clovis Oncology has established strategic collaborations, including license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH. The company also maintains a clinical collaboration with Bristol Myers Squibb Company and a partnership with Foundation Medicine, Inc. Founded in 2009, Clovis Oncology, Inc. is headquartered in Boulder, Colorado.
Prix de l'action
$0.10794012
Dernière synchronisation: 2022-12-15
Capitalisation boursière
$15.65M
Changement (1 jour)
-17.06%
Changement (1 an)
0.00%
Pays
US
Échange Clovis Oncology, Inc. (C6O)

Catégorie

Healthcare
Le prix C6O avec la capitalisation boursière de B
Clovis Oncology, Inc. Clovis Oncology, Inc.
C6O
$0.10794012
Capitalisation boursière de Clovis Oncology, Inc.(C6O)
Capitalisation boursière: $15.65M
En August 2026, Clovis Oncology, Inc. a une capitalisation boursière de $15.65M. Cela fait de Clovis Oncology, Inc. la 30759th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Clovis Oncology, Inc. du 2019 au 2026
C6O par rapport au top 5 des plus populaires stocks
Prix pour C6O L’actif B La capitalisation boursière de B Résultats
Clovis Oncology, Inc. Clovis Oncology, Inc.
$36,608.46 $15.65M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.307T +33,915,422.95%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$31,394.09 $15.65M
Apple Inc. Apple Inc.
AAPL
$4.551T +29,084,627.94%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$28,552.97 $15.65M
Alphabet Inc. Alphabet Inc.
GOOG
$4.139T +26,452,503.84%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$24,756.27 $15.65M
Microsoft Corporation Microsoft Corporation
MSFT
$3.589T +22,935,091.10%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$19,294.58 $15.65M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.797T +17,875,163.56%